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Summary
Objective: Magnetic resonance imaging (MRI) of articular cartilage has evolved to be an important tool in research on cartilage (patho)phys-
iology and osteoarthritis (OA). MRI provides a wealth of novel and quantitative information, but there exists no commonly accepted terminol-
ogy for reporting these metrics. The objective of this initiative was to propose a nomenclature for deﬁnitions and names to be used in scientiﬁc
communications and to give recommendations as to which minimal methodological information should be provided when reporting MRI-based
measures of articular cartilage in OA.
Methods: An international group of experts with direct experience in MRI measurement of cartilage morphology or composition reviewed the
existing literature. Through an iterative process that included a meeting with a larger group of scientists and clinicians (December 2nd, 2004,
Chicago, IL, USA), they discussed, reﬁned, and proposed a nomenclature for MRI-based measures of articular cartilage in OA.
Results: The group proposes a nomenclature that describes: (1) the anatomical location and (2) the structural feature being measured, each
name consisting of a metric variable combined with a tissue label. In addition, the group recommends minimal methodological information that
should be described.
Conclusions: Utilization of this nomenclature should facilitate communication within the scientiﬁc community. Further, the uniform adoption of
comprehensive nomenclature to describe quantitative MRI- features of articular cartilage should strengthen epidemiological, clinical, and phar-
macological studies in OA.
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has become an important diagnostic tool in research on car-
tilage (patho)physiology and osteoarthritis (OA). The tech-
nique has proven to be particularly powerful when
quantitative metrics that are continuous variables are
derived from serial magnetic resonance (MR) images, using
image segmentation and analysis algorithms. The use of
MRI biomarkers as endpoints shows great promise in the re-
search and management of OA as well as in the develop-
ment of disease modifying OA drugs1e6 and may also
have value with other joint diseases. Currently, however,
there exists no commonly accepted deﬁnition and terminol-
ogy for reporting these measures. That makes it difﬁcult to
compare different publications and extrapolate results so
that one study can inform another.
The objective of this initiative was to propose a nomencla-
ture of MRI-based measures of articular cartilage for use in
scientiﬁc reports, publications and databases, to facilitate
communication between researchers and to ensure that
comprehensive and high quality information on structural
features is reported. Similar efforts have been made in other
ﬁelds, such as bone histomorphometry, where the promul-
gation of standard nomenclature, symbols, and units7 led
to widespread use of a common language for measurement
between scientists, using comparable concepts of evalua-
tion. This, in turn, made it easier for the scientiﬁc community
to reach agreement upon how to interpret bone pathology
ﬁndings and spurred an enhanced appreciation for effects
of bone agents on bone histomorphometry8.
Methods
Upon invitation of the ﬁrst and senior author, an interna-
tional focus group of experts (the authors) with direct expe-
rience in quantitative MRI measures of cartilage
morphology or composition in OA was formed. After an in-
formal review of the existing literature, an initial draft of
the nomenclature was circulated amongst this ‘‘focus’’
group. This focus group then met on December 2nd, 2004
in Chicago (IL) (1) to discuss the proposal with a larger
group of invited scientists and clinicians from academia,
industry and government agencies (see Acknowledgment
section) and (2) working with this larger group, to propose
a nomenclature. Using a consensus approach, the group
proposed short parameter names based on consistent
rules, to keep naming conventions simple and easy to un-
derstand. The minutes of the meeting were circulated
amongst the focus group and the larger group for further re-
ﬁnement (one iteration in the larger group, and ﬁve itera-
tions within the focus group). The ﬁnal format of the
nomenclature and the recommendations was circulated
amongst and approved on by the authors, prior to submis-
sion. The same applied to the revised version of this
manuscript.
Results
The group recommends a modular approach to the no-
menclature: the ﬁrst label identiﬁes the anatomical location
of the measurement (anatomical label) and the second label
identiﬁes the ‘‘structural feature’’ being measured. Each
component should be separated by a full stop/period (‘‘.’’).
Another sufﬁx may be added to describe several statisti-
cal aspects of the structural feature being measured
(‘‘statistical label’’), or the central tendency (e.g. mean)
and dispersion (e.g. s.d.) can be described otherwise.ANATOMICAL LABELS
The current proposal deﬁnes anatomical labels of knee
joint cartilage, since the knee has been the focus of quanti-
tative MRI measurements of cartilage to date. Rules for
naming ‘‘anatomical labels’’ are: upper case digits label an-
atomically distinct cartilage plates with clear anatomical
boundaries (‘‘P’’¼ patella, ‘‘F’’¼ femur, and ‘‘T’’¼ tibia),
and modiﬁers (small case digits preceding the upper case
digits) may label anatomical subregions of these plates.
Based on these rules, labels for knee joint cartilage plates
are listed in Table I and displayed in Figs. 1 and 2.
Since the tibia bears two distinct cartilage plates with dif-
ferent degrees of involvement in different types of OA, it is
recommended that values for the medial tibia (‘‘MT’’) and
lateral tibia (‘‘LT’’) be reported separately (Fig. 1). Because
the femur (‘‘F’’) provides the bearing surface of different joint
compartments (femoropatellar, medial femorotibial, and lat-
eral femorotibial), the group recommends corresponding
anatomical labels to be used (Table I, Fig. 1). Further,
because the femoral cartilage plate is continuous through-
out these joint compartments, landmarks need to be deﬁned
for their separation. ‘‘TrF’’ (trochlea of the femur) may be
used for aspects of the femoral cartilage located anterior
TrF
LT MT
LT MT
cLF cMF
LT MT
pLF pMF
TrF
P
MT
cMF
pMF
P
LT
cLF
pLF
TrF
Fig. 1. Anatomical labels of knee joint cartilage plates. Sagittal
images (left row) and coronal images (right row).
976 F. Eckstein et al.: Nomenclature for MRI cartilage measuresto the intercondylar notch, and ‘‘MF’’ and ‘‘LF’’ for the medial
and lateral aspects of femoral cartilage posterior to it
(Fig. 1).
Because the femoropatellar joint displays anatomical fea-
tures separating a medial and lateral joint compartment9
(patellar ridge and trochlear groove), small letter modiﬁers
may be used to deﬁne subregions (Fig. 2): ‘‘mP’’ and
‘‘mTrF’’ for the medial aspects of the patella and trochlea,
and ‘‘lP’’ and ‘‘lTrF’’ for the lateral aspects. ‘‘cP’’ and
‘‘cTrF’’ may be used for the central aspect of the cartilage
plates (around the ridge and groove e Fig. 2), but authors
must report precisely how these regions are deﬁned.
The femoral condyles have frequently been separated
into two or more components. The ﬁrst contains the femoral
cartilage that is in contact with the tibial cartilage or menis-
cus (during standing and walking). The group suggests
these regions to be named central medial and central lateral
femur (‘‘cMF’’ and ‘‘cLF’’). The second component is lo-
cated posterior to the central area (Fig. 1) and does contact
with the tibia only during knee ﬂexion. This is suggested to
be named posterior medial and posterior lateral femur
(‘‘pMF’’ and ‘‘pLF’’). Note that ‘‘cMF’’ and ‘‘cLF’’ are directly
interposed between ‘‘TrF’’ (anteriorly), and ‘‘pMF’’ and
‘‘pLF’’ (posteriorly). The group does not give a speciﬁc rec-
ommendation to where the separation should be made,
since no obvious anatomical landmark exists to separate
these regions and since there exist several reasonable pro-
posals in the literature. However, authors are urged to give
comprehensive information on how the separation is made.
mP
cP
lP
lTrF
a
cAB cAB
dAB
tAB
AC AC
b
cAB dAB
cMF.AC
cMF.tAB
c
ThCcAB 0mm
cMF.ThCtAB
d
Fig. 2. (a) Anatomical labels of knee joint cartilage plates and (b)
cartilage morphology labels for measurements of areas on axial im-
ages. This example displays an area of denuded cartilage in the
center of the patella; (c) cartilage morphology labels for measure-
ments of areas and (d) for measurements of cartilage thickness
in the medial femoral condyle. This example displays an area of de-
nuded cartilage in the external aspect of the medial femoral con-
dyle. Note that the peripheral osteophyte is not included in the
measurement of tAB. When reporting values for cartilage thickness,
it is important to differentiate whether or not the values include de-
nuded areas (‘‘dAB’’) as areas of 0 mm cartilage thickness. The
group recommends the use of ‘‘ThCtAB’’ for measurements includ-
ing ‘‘dAB’’ (0 mm cartilage thickness) and ‘‘ThCcAB’’ for those only
including cartilage.The regions of interest on the femoral condyles are different
from the ICRS cartilage injury evaluation package (http://
www.cartilage.org/ﬁles/ICRS_evaluation.pdf) and other
publications10. An explanation on why a different anatomi-
cal separation is proposed is contained in a footnote of
Table I.
CARTILAGE MORPHOLOGY LABELS
A number of studies have investigated the accuracy of
morphological variables as derived from MRI in healthy
andOA subjects11e26 and their ability to characterize change
longitudinally27e32. The group recommends the following
rules for naming ‘‘morphology labels’’: Lower case modiﬁers
should come ﬁrst (t¼ total, c¼ covered by cartilage, and
d¼ denuded of cartilage). These should be followed by an
upper case ‘‘geometric label’’ (A¼ area, V¼ volume, and
Th¼ thickness) and then by an upper case identiﬁer of the
tissue being measured (B¼ subchondral bone and
C¼ cartilage). These rules permit researchers easily to
adapt the nomenclature for new modiﬁers, metric variables,
tissues (e.g. synovial ﬂuid, menisci, osteophytes), or joints.
Based on these rules, the following morphological cartilage
labels were proposed (Table II).
The actual interface between cartilage and the subchon-
dral bone is the cartilage-covered area of subchondral bone
(‘‘cAB’’). The unit recommended for human studies is cm2,
and that for small animal studies is mm2. Areas of (original,
premorbid) subchondral bone with full thickness cartilage
defects or central osteophyte growth are termed the de-
nuded (eroded) area of subchondral bone (‘‘dAB [unit¼ cm2
or mm2]). The sum of ‘‘cAB’’ and ‘‘dAB’’ is the total area of
subchondral bone (‘‘tAB’’ [unit¼ cm2 or mm2]). Although re-
modeling of the subchondral bone occurs in OA, the size of
‘‘tAB’’ can be interpreted as an estimate of the original, pre-
morbid area of subchondral bone and a useful proxy for
bone size, which may be used to normalize cartilage vol-
ume to joint size36. For this reason, peripheral osteophytes
are not included in measurements of ‘‘cAB’’, ‘‘dAB’’ and
‘‘tAB’’, since otherwise the premorbid bone area may be
overestimated (Fig. 2). Because central osteophytes repre-
sent areas of original, premorbid subchondral bone that is
denuded of original cartilage, they are regarded as dAB,
and segmentation of tAB may be performed by connecting
the cAB surrounding the osteophyte through its base (at the
location of the original subchondral bone). Note that ‘‘cAB’’
and ‘‘dAB’’ can be expressed as a percentage of ‘‘tAB’’
(‘‘cABp’’ or ‘‘cAB%’’, ‘‘dABp’’ or ‘‘dAB%’’). In a healthy, pre-
morbid joint, ‘‘cAB’’ is identical to ‘‘tAB’’, ‘‘cABp’’/’’cAB%’’ is
100%, and ‘‘dABp’’/’’dAB%’’ is 0%. ‘‘dAB’’ may consist of
one or several areas. ‘‘NdAB’’ may be used to additionally
report the number of (topographically separate) denuded
bone areas.
The area of the cartilage surface (‘‘AC’’ [unit¼ cm2 or
mm2]) may be used to describe the size of cartilaginous joint
surface that provides the bearing surface of joints (Fig. 2).
‘‘AC’’ is similar but not identical in size to ‘‘cAB’’ and does
not include areas of full thickness defects (‘‘dAB’’).
The volume of the cartilage (‘‘VC’’ [unit¼mm3 or ml]) rep-
resents all articular cartilage, with exception of the cartilage
cover of osteophytes. Since ‘‘VC’’ scales with bone si-
ze17,33e37, ‘‘VC’’ may be reported additionally as divided
by ‘‘tAB’’ (’’VCtAB’’ [unit¼mm3/mm2 or ml/mm2¼mm]).
This is important, because ’’VCtAB’’ has been shown to per-
form better than ‘‘VC’’ in differentiating subjects with and
without OA37,38.
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Anatomical labels of the proposed nomenclature (knee joint)
Label Explanations Guidelines/recommendations
Knee
K Knee, total (PþMTþ LTþ F)
P Patella
T Tibia (MTþ LT) Always give data for MT and LT separately
MT Medial tibia
LT Lateral tibia
F Femur, total (TrFþMFþ LF) Give data for TrF, MF, and LF separately
TrF Femoral trochlea (ant. to intercondylar notch)
MF* Medial femoral condyle (post. to intercond. notch) Give data for cMF and pMF separately
LF* Lateral femoral condyle (post. to intercond. notch) Give data for cMF and pMF separately
Patella Subregions
cP Central aspect of patella (around main ridge) Borders need to be deﬁned
mP Medial aspect of patella (medial facet) Medial to main ridge
lP Lateral aspect of patella (lateral facet) Lateral to main ridge
Trochlea Subregions
cTrF Central aspect of trochlea (around groove) Borders need to be deﬁned
mTrF Medial aspect of trochlea (medial facet) Medial to main ridge
lTrF Lateral aspect of trochlea (lateral facet) Lateral to main ridge
Femoral
condyle*
Subregions
cMF Central medial femoral condyle (anterior aspect of condyle) Border between cMF and pMF needs to be deﬁned
pMF Posterior medial femoral condyle (posterior aspect of condyle) Border between cMF and pMF needs to be deﬁned
cLF Central lateral femoral condyle (anterior aspect of condyle) Border between cMF and pMF needs to be deﬁned
pLF Posterior lateral femoral condyle (posterior aspect of condyle) Border between cMF and pMF needs to be deﬁned
*The proposal to separate the femoral condyles into two anatomical regions of interest (c and p, respectively) is in contrast to the ICRS
cartilage injury evaluation package (http://www.cartilage.org/ﬁles/ICRS_evaluation.pdf) and other publications in the literature10. These
have divided the femoral condyles into three regions (anterior, central and posterior). In the current nomenclature, the ‘‘anterior’’ region of
the femoral condyle (between the trochlea and the region of the femoral condyle that is in contact with the tibia during standing) was discarded,
because this region would be very small, difﬁcult to deﬁne (dependence on knee ﬂexion angle) and thus less suitable for quantitative mea-
surements. If authors would like to measure this part of the femoral condyle (between the trochlea and tibial contact zone) separately or dis-
card it from measurements of cMF or cLF (i.e. because chemical shift from the patellar fat pad may introduce error to measurements of T1 or
T2) this should be clearly stated in the manuscript.When reporting values for cartilage thickness (‘‘ThC’’)
[unit¼mm or mm], it is important to clearly differentiate
whether the values include denuded areas (‘‘dAB’’) as
areas of 0 mm cartilage thickness (Fig. 2). The group rec-
ommends the use of ‘‘ThC’’ as either ‘‘ThCtAB’’for measure-
ments including ‘‘dAB’’ (0 mm cartilage thickness) or
‘‘ThCcAB’’ for measurement of only the regions with carti-
lage coverage (Fig. 2).
Note that ‘‘ThCcAB’’ may or may not decrease in OA,
because areas of thin articular cartilage that progress to
full thickness lesions will no longer be included, whereas
the remaining cartilage may become thinner, remain unal-
tered or even swell. To report ‘‘ThCtAB’’, 0 mm cartilage
thickness values need to be added for ‘‘dAB’’ and
weighted in proportion to values from ‘‘cAB’’. ‘‘ThCtAB’’
and ’’VCtAB’’ should be very similar in the same cartilage
plate, since they represent two methods of computing the
same entity (thickness). However, values are usually not
identical because different methodologies are applied. It
is therefore recommended that both variables be reported
independently (Table III).
When reporting metric variables of cartilage thickness,
authors will want to report the mean, median, maximum,
minimum, s.d., coefﬁcient of variation, or other descriptive
statistical aspects of the thickness values measured within
one cartilage plate. The authors may want to note that
they report means or s.d.’s, etc., or they may add, a sufﬁx
that includes abbreviations of these statistical measures.CARTILAGE COMPOSITION LABELS
Various methods for compositional imaging have been
described, but only delayed gadolinium enhanced magnetic
resonance imaging (dGEMRIC)39e42 and T2 mapping of
cartilage43e50 (Fig. 3) were felt to be sufﬁciently explored
to date to be included in a nomenclature. However, the no-
menclature presented here is easily adaptable to other
compositional variables. As compositional labels, ‘‘DG’’
(dGEMRIC index value [unit ms]) and ‘‘T2’’ (T2 relaxation
time [unit ms]) are proposed in conjunction with a ‘‘C’’ for
cartilage (Table II).
‘‘VlDGC’’ is to be used to express the volume [unit mm3
or ml] of low dGEMRIC values (voxels) below a threshold
value [in ms] as a measure of size of a compositional carti-
lage lesion. The threshold that is used to deﬁne a dGEMRIC
lesion should be stated (e.g. <350 ms). To express how
large ‘‘VlDGC’’ is in relation to all cartilage (or of the carti-
lage within a speciﬁc zone) ‘‘VlDGCp’’ or ‘‘VlDGC%’’
[VlDGC/VC 100%, unit %] may be reported. However,
this may provide an insufﬁcient relative measure if a large
proportion of the cartilage has been lost. ‘‘VlDGCtAB’’
[VlDGC divided by tAB; unit¼mm3/mm2) may then be pref-
erable. If values for the ‘‘DGC’’ are not derived volumetri-
cally, but from a single slice, it is recommended that the
term ‘‘AlDGC’’ [area, unit¼mm2) be used and ‘‘AlDGC%’’
or ‘‘AlDGCp’’ and ‘‘AlDGCtLB’’ [tLB¼ total length of bone
within the slice in mm].
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Morphological and compositional labels of the proposed nomenclature
Label Explanations Guidelines/recommendations
Morphology
tAB Total area of subchondral bone (dABþ cAB) Represents premorbid subchondral bone
area, peripheral osteophytes to be excluded,
base of central osteophytes to be included
cAB Area of subchondral bone covered
with cartilage (tAB covered by AC)
cAB% [cABp] Percent of subchondral bone covered
with cartilage (cAB/tAB 100%)
dAB Area of subchondral bone, denuded,
eroded, full thickness defect
(tAB not covered by AC)
dAB% [dABp] Percent of subchondral bone area
that is denuded (dAB/tAB 100%)
AC Area of cartilage surface dAB not included
VC Volume of cartilage Specify technical implementation (see text)
VCtAB Volume of cartilage divided by total
area of subchondral bone (VC/tAB)
Accounts for differences in bone size
NdAB Number of (separate) cartilage denuded areas
ThCtAB Cartilage thickness over total
subchondral bone area; denuded
areas counting as 0 mm thickness
Specify technical implementation
(see text); Add statistical label
for database purposes
ThCcAB Cartilage thickness over cartilaginous
area of subchondral bone;
denuded areas not included
Specify technical implementation (see text);
Add statistical label for database purposes
Composition
DGC dGEMRIC index value across cartilage
VlDGC Volume of low dGEMRIC index
values below certain threshold
Threshold needs to be speciﬁed
VlDGC% [VlDGCp] Percent cartilage volume of dGEMRIC
index value below certain threshold
(VlDGC/VC 100%)
Threshold needs to be speciﬁed
VlDGCtAB VlDGC divided by tAB (VlDGC/tBA) Accounts for differences in bone size
T2C T2 value across entire cartilage Should be given for different layers/zones
(sz¼ superﬁcial zone, mz¼middle
zone, dz¼ deep zone); Add statistical
label for database purposes
VhT2C Volume of high T2 value above certain threshold Threshold needs to be speciﬁed
VhT2C% Percent cartilage volume of high T2
above certain threshold (VhT2C/VC 100%)
Threshold needs to be speciﬁed
VhT2CtAB Volume of high T2 value above certain
threshold divided by tAB (VhT2C/tAB)
Accounts for differences in bone size
VlT2C Volume of T2 low value below certain threshold Threshold needs to be speciﬁed
VlT2C% Percent cartilage volume of low T2 below
certain threshold (VlT2C/VC 100%)
Threshold needs to be speciﬁed
VlT2CtAB Volume of low T2 value below certain
threshold divided by tAB (VlT2C/tAB)
Accounts for differences in bone sizeSimilar considerations apply to the analysis of T2 relaxa-
tion times of articular cartilage: the T2 value may be given
throughout the entire cartilage (‘‘T2C’’ [unit¼ms]). How-
ever, because ‘‘T2’’ may vary as a function of distance
from ‘‘AC’’ to ‘‘cAB’’5,43,49, values may be reported for a su-
perﬁcial zone (e.g. ‘‘szT2C’’); ‘‘mz’’ and ‘‘dz’’ may be used
as modiﬁers preceding the compositional label for the mid-
dle and deep zones, respectively.
Whether cartilage is separated in two (sz and dz) or three
zones (sz, mz and dz), the extension of the layers should
always be clearly deﬁned, preferably as percent values of
the distance from the cartilage surface (as used to compute
‘‘AC’’, 0%) to the bone surface (as used to compute ‘‘cAB’’,
100%).
In contrast to ‘‘DGC’’ both low (e.g. <xx ms [speciﬁc
values depending on joint, cartilage plate, depth throughout
the tissue, and how T2 is measured]) and high values (e.g.
>xx ms) may indicate a lesion (Fig. 3). ‘‘VlT2C’’ may beused to express the volume [unit mm3 or ml] of voxels with
low T2 values and ‘‘VhT2C’’ that with high T2 values. The
same relative measures may be used for lesion size as
have been described for ‘‘DGC’’ previously (Table II). Since
T2 values can depend on the measurement method, echo
spacing and other parameters should be explicitly reported
(see below).
Both for dGEMRIC and T2, describing means or other
measures of central tendency and measures of dispersion
such as s.d. (by sufﬁx or otherwise) are recommended.
GUIDELINES FOR MINIMAL METHODOLOGICAL INFORMATION
The group recommends some minimal methodological in-
formation that should be provided when reporting the above
metric variables. Please note that general requirements for
reporting of methods of clinical and preclinical studies have
been formulated previously and should serve as primary
979Osteoarthritis and Cartilage Vol. 14, No. 10guidelines. The following speciﬁc information was deemed
particularly important in the context of quantitative MRI stud-
ies on articular cartilage:
a) Sample information/studies on human subjects
 Number of patients or healthy volunteers, gender (dis-
tribution), age (range and s.d.), ethnicity
 Method(s) for subject recruitment/selection
 Joint(s) examined (right, left, dominant, non-dominant,
signal, non signal)
 Grade of osteoarthritis (symptomatic, asymptomatic,
Kellgren Lawrence Grade)
 Axial alignment, if measured, and type of measurement
(weightbearing ap knee radiographs or full limb hip-to-
ankle images)
Table III
Examples of nomenclature
Example variable Explanation
Cartilage morphology
P.tAB Total subchondral bone area in the patella
MT.VCtAB Cartilage volume divided by total
subchondral bone area of the medial tibia
mTrF.CThtAB Cartilage thickness (over total subchondral
bone area) of the medial femoral trochlea
Cartilage composition
LT.VlDGC Volume of low dGEMRIC values (below
certain threshold) in the lateral tibia
lP.szT2C T2 in the superﬁcial zone (to be deﬁned)
of the lateral patellar facet
MF.VhT2CtAB Volume of high T2 values (above speciﬁed
threshold) of the medial femoral condyle,
divided by the total subchondral bone
area to account for differences in bone size Loading conditions of the knee during or prior to imag-
ing (period of rest or unloading, traction)
 Type of analysis (inter- or intra-subject comparisons,
cross sectional or longitudinal analysis), power
calculation
b) Sample information/animal models and cartilage samples
 Number of animals/samples, species and speciﬁc
strain, gender
 Age (range and s.d.); level of skeletal maturity; develop-
mental stage
 Joint(s) examined (right, left, treated, contralateral)
 Type of intervention (spontaneous model; surgical e
what type? enzymatic e what agent? what dosage?)
 Anesthesia used for MR scanning, and any physiologi-
cal parameters monitored
 Details of joint positioning joint in coil (ﬂexion angle)
 Time between intervention and MR examination, level
of physical activity in between
 Inter- or intra-subject comparisons (cross sectional or
longitudinal analysis)
 Temperature of specimens/samples during imaging
 Media in which samples have been equilibrated (e.g.
protease inhibitor vs saline)
c) MRI acquisition conditions
 Magnetic ﬁeld strength, MR scanner and coil type
 Quality assurance (QA) or control (QC) procedures in
scanner maintenance and potential drift in scanner gra-
dient calibration
 Scan orientation (sagittal, coronal, axial, or double obli-
que orientated perpendicular/parallel to.)
 Were parallel imaging methods used?
 Angle between B0 and the cartilage surface under in-
vestigation (to assist interpretation of magic angle
effects)DG index
T1
Gd 
(ms)
200
320
430
550
670
800
Example
of high
dGEMRIC
index
values
Example
of low
dGEMRIC
index
values
0
80
255
T
2
(ms)
Fig. 3. Examples of dGEMRIC. The ﬁgure displays a person with high dGEMRIC values (top left) and one with low dGEMRIC values (bottom
left). Because chemical shift from the patellar fat pad may introduce error to measurements, the areas of cartilage adjacent to it should be
discarded. Examples of T2 mapping of the knee, axial orientation (top right) and sagittal orientation (bottom right). The arrow (top right) in
the enlarged portion of the patella cartilage highlights a T2 lesion. Note the magic angle effects at 55( on the T2 examples.
980 F. Eckstein et al.: Nomenclature for MRI cartilage measures Imaging sequence and measure of validity (accuracy)
and precision (reproducibility)
 Number of slices acquired
 Repetition time (TR), echo time (TE), bandwidth
 Flip angle (FA) and, in the case of cartilage composition
measures, variability in ﬂip angle across the joint either
due to mis-set pulses, or due to transmitter radiofre-
quency inhomogeneity
 Number of acquisition averages (NEX)
 Slice- or phase oversampling if >0%, elliptical scanning
(if on), asymmetric echo (if allowed)
 Field of view (FOV), matrix, in-plane resolution (with or
without interpolation), slice thickness, phase resolution
(if less than 100%), slice resolution (if less than 100%)
 Image acquisition time for each sequence
 Fat saturation: prepulse or water excitation
 Non-fat-suppressed images: size (in mm) and direction
of chemical shift artifact
 dGEMRIC: dose of intravenous Gd(DTPA) injection;
type and time of joint motion between injection and im-
age acquisition; time between injection and image
acquisition, cut off value (<xx ms) that deﬁnes a lesion
 T2: Type of pulse sequence utilized, number of echoes
acquired to calculate T2 and inter-echo spacing of the
echo train used to calculate T2, methods used to reduce
stimulated echo and mixed T1/T2 contrast. Were T2
phantom measurements performed on a regular basis?
d) Image analysis
 Deﬁnition of anatomical regions/subregions, in particu-
lar borders not corresponding to clear anatomical land-
marks (e.g. cMF vs pMF)
 Data analyzed by one reader or by several readers,
level of training of readers, measure of reliability (accu-
racy, repeatability) in view of reader intervention
 Time sequence of image analysis, e.g. longitudinal data
(baseline, follow-up) read in pairs, unblinded to se-
quence of acquisition; longitudinal data read in pairs,
blinded to sequence of acquisition; longitudinal data
read randomly, blinded to subject ID
 2D analysis (within one slice or several slices) vs 3D
analysis (across slices, independent of slice
orientation)
 Detailed methodological description how quantitative
parameters were calculated
 Level of interpolation of data (in-plane, thickness) prior
to segmentation
Specific to cartilage morphology
B Volume measurements: numerical integration of seg-
mented voxels or surface reconstruction model
B Surface areas computation: 2D (length of con-
tours slice thickness) or 3D (triangulation or
other)/degree of smoothing, if applied
B Thickness computations: 2D (within slice) or 3D (in-
dependent of slice orientation); Euclidean distance
transformation (EDT), vector method, other; direction
from cAB to AC or from AC to cAB
Specific to cartilage composition
B Registration used to align images for computing T1
or T2, 2D or 3D/translation and/or rotation/rigid or
non-linear
B Method of dGEMRIC index computation: map vs uni-
voxel method
B Processing algorithm for determining T2 (2 vs 3 pa-
rameter ﬁt),B Number of echoes and inter-echo spacing of the
echo train used to calculate T2
B Spatial variation of T2 characterization
B Cut off value (< or >xx ms) that deﬁnes a lesion
Discussion
The objective of this initiative was to propose a nomencla-
ture of metric variable names to be used in scientiﬁc
communications of quantitative MRI-based measures of
articular cartilage in OA, and to give recommendations as
to which minimal methodological information should be pro-
vided. Please note that this proposal on nomenclature should
neither be construed as an endorsement of particular metric
variables that might be most useful in characterizing OA
(pathophysiological validity), nor an endorsement about the
accuracy and reproducibility of any particular metrics (techni-
cal validity). Also, we do not endorse speciﬁc techniques or
methodologies on how these measures should be obtained.
No previous publication has promulgated a comprehensive
and widely accepted set of guidelines and nomenclature to
include anatomical, morphological and compositional labels
of knee joint cartilage. By doing this we hope to promote uni-
form reporting of these measurements.
A strength of the modular nomenclature proposed here is
that it is systematic, consistent, and easily adaptable to
technical innovation and to new anatomical, morphological,
compositional and tissue labels. The parameter names de-
liberately do not enforce the use of a speciﬁc methodology,
in order to gain wide acceptance throughout the scientiﬁc
community.
A limitation of the current nomenclature is that some of
the recommendations (as for instance the subdivision in
the patellar and femoral cartilage, and some of the morpho-
logical and compositional labels) are primarily ‘‘opinion-
based’’. The current proposal should thus be considered
as work in progress and may need to be revised from
time to time, based on further scientiﬁc evidence emerging.
Also, this nomenclature is designed to describe cartilage
changes occurring in OA and is less suitable for cartilage
undergoing surgical manipulation and repair. MRI-based
technologies may be developed further for the latter pur-
pose, and the nomenclature may therefore need to be
extended in this respect in the future. Since quantitative pa-
rameters on non-cartilage tissues are of increasing interest
in the realm of OA, the nomenclature may also have to be
expanded in the future to include other tissues. However,
during the meeting it was decided that further exploration
was necessary before a nomenclature of non-cartilaginous
tissues can be established.
Widespread utilization of this nomenclature should facili-
tate communication and avoid misunderstandings amongst
statisticians, data managers, investigators, drug developers
and regulators. The nomenclature should aid the scientiﬁc
community in agreeing upon how to interpret pathological
ﬁndings in OA and treatment effects on cartilage. The
nomenclature may consolidate and disseminate the exper-
tise of scientists in the ﬁeld by informing others which mea-
surement parameters are central. This, in turn, should
substantially strengthen the use of quantitative MRI-based
measures of articular cartilage in epidemiological, clinical,
and pharmacological studies in OA research.
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